An update from Purple Biotech ( (PPBT) ) is now available.
On April 22, 2025, Purple Biotech Ltd. held its Annual General Meeting of Shareholders, where several proposals were voted on. The shareholders approved the re-election of three directors, Eric Rowinsky, Robert Gagnon, and Ido Agmon, to serve until 2028. Additionally, there was a significant increase in the company’s authorized ordinary share capital, expanding from 1 billion to 100 billion shares. This expansion could potentially enhance the company’s financial flexibility and support future growth initiatives.
Spark’s Take on PPBT Stock
According to Spark, TipRanks’ AI Analyst, PPBT is a Underperform.
Purple Biotech faces significant hurdles with persistent revenue and profitability challenges reflected in its financials. Despite a strong balance sheet, negative cash flow and valuation metrics underscore the financial distress. Technical analysis offers mixed signals, with some short-term momentum but overall weakness. Such factors contribute to a below-average stock score, highlighting the risks and need for strategic improvement.
To see Spark’s full report on PPBT stock, click here.
More about Purple Biotech
Purple Biotech Ltd. operates in the biotechnology industry, focusing on developing innovative cancer therapies. The company is headquartered in Rehovot, Israel, and is involved in research and development to advance its pipeline of oncology products.
YTD Price Performance: -38.13%
Average Trading Volume: 18,830
Technical Sentiment Signal: Hold
Current Market Cap: $7.19M
See more data about PPBT stock on TipRanks’ Stock Analysis page.